Celldex Completes Phase 3 Enrollment for Barzolvolimab in Chronic Urticaria Trials

Key Facts

1Celldex completed enrollment in the global Phase 3 program of barzolvolimab for chronic spontaneous urticaria (CSU).

21,939 patients were enrolled across 43 countries, making it the largest program in antihistamine refractory CSU.

3The program consists of two global Phase 3 trials: EMBARQ-CSU1 and EMBARQ-CSU2.

Celldex Therapeutics (NASDAQ: CLDX) has successfully completed patient enrollment for its global Phase 3 clinical program evaluating barzolvolimab. The program, focused on treating chronic spontaneous urticaria (CSU), includes two pivotal trials, EMBARQ-CSU1 and EMBARQ-CSU2. A total of 1,939 patients across 43 countries were enrolled, representing the largest clinical program ever conducted for antihistamine-refractory CSU. This milestone is significant for the biotech firm as it establishes a clear path toward top-line data results and potential regulatory filing. Barzolvolimab aims to provide a new therapeutic option for patients who do not respond to standard antihistamine treatments. Investors view this progress as a reduction in execution risk for Celldex's lead drug candidate.